{"id":"W4405181643","doi":"10.1158/1538-8514.cancerchem24-pr001","title":"Abstract PR001: Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Adenosine; Medicine; Adenosine receptor; Pharmacology; Adenosine A2A receptor; Receptor; Immunology; Internal medicine; Agonist","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001381002,0.0002661382,0.0002745735,0.00008386363,0.00005500175,0.00008200487,0.0001546128,0.0001961892,0.00002577954],"category_scores_gemma":[0.000006204858,0.0002391778,0.0001489018,0.0001579505,0.0001235196,0.00001524041,0.00004956722,0.0001464802,5.910117e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000505995,"about_ca_system_score_gemma":0.0002066795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002611328,"about_ca_topic_score_gemma":0.0001136669,"domain_scores_codex":[0.9986751,0.00002701062,0.0003445204,0.0004570945,0.0001607022,0.0003355485],"domain_scores_gemma":[0.9995016,0.00003589148,0.00009577843,0.000259536,0.0000630927,0.00004408882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004233378,0.00007372337,0.001408629,0.0003215142,0.0004556064,0.00001607746,0.0002173986,0.000389251,0.9881343,0.0003200312,0.001170246,0.007069833],"study_design_scores_gemma":[0.001289747,0.0003002178,0.001228415,0.0003518302,0.00009881442,0.00001115952,0.00008680049,0.0004588838,0.7406991,0.0001805661,0.2548663,0.0004281785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.793966,0.200262,0.002735581,0.001804524,0.0004429588,0.0004181852,0.000284149,0.00002620765,0.00006040985],"genre_scores_gemma":[0.9772446,0.02083769,0.0002623509,0.0006273827,0.0003191263,0.0001805433,0.00007722845,0.0001066217,0.0003444843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2536961,"threshold_uncertainty_score":0.9753385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01673330027036038,"score_gpt":0.2919811217501078,"score_spread":0.2752478214797474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}